Mayo Clinic, Kaiser among health giants investing $110M into home care company

A handful of healthcare heavyweights are investing $110 million into a Boston-based company using technology-focused strategies to provide acute care in patients’ homes.

Baxter International, Global Medical Response, Cardinal Health, Mayo Clinic and Kaiser Permanente announced the new capital infusion into Medically Home on Monday. The latter two groups are providing additional money on top of their prior $100 million investment made back in May while Cardinal Health is also upping its original dollar contribution.

Medically Home helps facilitate and coordinate treatment for high-acuity conditions outside hospital walls. To date, the company says it has treated more than 7,000 patients using its platform.

“The addition of these strategic national partners powerfully strengthens our logistics capability which our health system providers need to safely and reliably care for patients in their homes,” CEO of the firm Rami Karjian said in a statement. “The accelerating decentralization of high acuity care from hospitals and other institutional sites to an ever-increasing number of patients' homes enabled by Medically Home, validates the importance of an ecosystem of healthcare partners working together on behalf of patients and the clinicians that care for them across the country.”

The company also announced that Baxter, Global Medical Response and Cardinal Health will each have representatives on Medically Home’s board.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?